Hexima Limited (ASX: HXL)
Health Care · Biotechnology · AU
AU$—
— today · — 1Y
Hexima Limited (ASX: HXL) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.44M.
trading between 0.03 and 0.09.
Tweenvest scores Hexima Limited across four factors: quality 37/100, value 68/100. Its strongest factor is value.
HXL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.44M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.01
- Dividend yield
- —
- Beta (5Y)
- 0.87
- 52-week high
- AU$0.09
- 52-week low
- AU$0.03
- Avg volume (3M)
- —
- Shares outstanding
- 41.76M
- Employees
- —
- Next earnings
- —
About Hexima Limited
Hexima Limited is a biotechnology firm focused on the discovery and advancement of plant-derived proteins and peptides for medical applications in humans. Its primary drug candidate, pezadeftide, a plant defensin, is presently undergoing Phase IIb clinical evaluations in Australia and New Zealand to address fungal toenail infections. The company was established in 1997 and its main operations are situated in Preston, Australia.
- ISIN
- AU0000111932
- Founded
- 1997
- Listed since
- Nov 30, 2020
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Halberd CorporationOTCPK: HALB | $1.49M | $0.00 | +100.00% |
| Curis, Inc.NasdaqCM: CRIS | $1.48M | $0.71 | -3.69% |
| BioSenic S.A.ENXTBR: BIOS | $1.47M | €0.00 | -9.09% |
| Silexion Therapeutics CorpNasdaqCM: SLXN | $1.45M | $0.23 | -9.62% |
| Protagenic Therapeutics, Inc.OTCPK: PTIX | $1.40M | $0.77 | -15.34% |
| Bone Biologics CorporationNasdaqCM: BBLG | $1.31M | $0.47 | -1.33% |
| AXIM Biotechnologies, Inc.OTCPK: AXIM | $1.25M | $0.00 | -4.83% |
| Alligator Bioscience AB (publ)OM: ATORX | $1.21M | Skr0.02 | -16.58% |
Figures last refreshed Oct 4, 2026.